This is particularly important for individuals with additional risk factors such as renal impairment, elderly patients, those taking multiple glucose-lowering medications, or anyone with a history of gastrointestinal disorders or pancreatitis
Finally, a phase 2 study in subjects with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis at doses of 2.4 mg, 4.8 mg, and 6.0 mg, compared to placebo over 48 weeks, results in significant improvement of liver fat content and fibrosis, with mean weight reductions of 10%, 13%, 13%, and 0.7%, respectively (98)
J.OrskovC
It has changed my life. Addiction is like a record playing in your mind, and that song always ends in using drugs or alcohol, Klein says